Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Karyopharm Therapeutics
Multiple GPRC5D Agents For Myeloma Raise Questions On Positioning
J&J’s talquetamab is in the lead among bispecific antibodies, while Roche and BMS are not far behind. Presentations at ASH sparked discussion on how to position them in treatment.
Finance Watch: No New IPOs, But Two Firms Take The SPAC Route
Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.
The Real World Is Not Enough: Comparability Is Common Obstacle For RWE In US FDA Decisions
Unsuccessful attempts to use real-world evidence for approvals highlight the need to demonstrate relationship between real-world data and clinical trial patients. The Pink Sheet examines what went wrong for Bluebird/Bristol’s Abecma, Ultragenyx’s Dojolvi, and Karyopharm’s Xpovio.
Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder
In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.
- Other Names / Subsidiaries
- NPM Pharma, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.